Lilly's scientist CEO preps for 'Year Y'

What haunts Lilly CEO John Lechleiter's work anxiety dreams? Year Y and Year Z. They're the continuation of a series that began in 2001, a.k.a. Year X, when the blockbuster antidepressant Prozac went off patent. Year Y will be plagued by the loss of Zyprexa exclusivity. Year Z? Cymbalta. "It's part of our business model," Lechleiter told the Financial Times in an interview, "we have a period of time, and then these things become pumpkins."

Obviously, Lilly has experience with sudden loss of revenue. When Prozac turned into an orange gourd, it left a castle-sized hole in sales. Lechleiter believes the company can patch the holes in Years Y and Z by licensing products, buying innovative biotechs, striking edgy risk-sharing deals, and so on. Lilly will get its hands on the biologic drugs and diagnostics and other assets it needs to bridge Y and Z. No need for a castle-sized acquisition, he promises, just as he has been throughout the 2009 M&A epidemic.

"We're betting on an innovation strategy: that we will not for ever be stuck in an innovation drought," he says. "Science and our insight into human biology argue for a much stronger flow of products in the years ahead."

And unlike his counterparts at other Big Pharmas these days, Lechleiter actually does have insight into human biology. He's a research chemist. Does this science background implies an advantage for Lechleiter? Or do his rivals with their MBAs and consumer-goods experience have the upper hand in today's pharma market?

- read the FT profile

Poll: Does having a non-scientist CEO negatively impact innovation at drug companies? Vote

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.